DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

  • Transformative surfaceome discovery technology enables a comprehensive map of the cancer cell surface to identify a multitude of novel druggable targets.
  • Pipeline programs in Small Cell Lung Cancer and Microsatellite-Stable Colorectal Cancer.
  • Experienced team of individuals with expertise in surface proteomics and oncology from academia, biotech and pharma, led by CEO Roman Thomas.
  • Leading biopharma executives Dieter Weinand (previously CEO at Bayer Pharmaceuticals) and Carsten Reinhardt (CDO at Immatics), join the DISCO Board of Directors as Chairman and Independent Director, respectively.

COLOGNE, Germany and ZURICH, Switzerland Jan. 16, 2024 – DISCO Pharmaceuticals (“DISCO”), a specialist biotech unlocking the surfaceome of cancer cells at scale to identify new targets and develop first in class drugs, emerges from stealth today. The Company, operating out of Cologne, Germany and Schlieren, Switzerland, successfully raised seed financing of EUR 20 million and is backed by a world leading investor syndicate, including Sofinnova Partners, which led the round, Panakes Partners, M Ventures and AbbVie Ventures.

Read more…